DZ Bank Analysts Give Roche (VTX:ROG) a CHF 270 Price Target

Roche (VTX:ROG) has been assigned a CHF 270 price objective by equities researchers at DZ Bank in a report issued on Friday, February 2nd. The firm presently has a “buy” rating on the healthcare company’s stock. DZ Bank’s price objective would suggest a potential upside of 23.32% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Morgan Stanley set a CHF 260 price target on Roche and gave the company a “neutral” rating in a research note on Friday, October 6th. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a research note on Monday, October 9th. UBS Group set a CHF 260 price target on Roche and gave the company a “neutral” rating in a research note on Monday, October 9th. Goldman Sachs Group set a CHF 325 price target on Roche and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, Credit Suisse Group set a CHF 260 price target on Roche and gave the company a “neutral” rating in a research note on Monday, October 16th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of CHF 257.20.

Shares of Roche (VTX ROG) opened at CHF 218.95 on Friday. Roche has a 52 week low of CHF 214.30 and a 52 week high of CHF 273. The firm has a market capitalization of $189,580.00 and a price-to-earnings ratio of 21.81.

TRADEMARK VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/13/roche-rog-pt-set-at-chf-270-by-dz-bank.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply